Endocrine Abstracts

Introduction: Sodium/glucose co-transporter 2 (SGLT2) inhibitors are a relatively new group of antihyperglycaemic medications for type 2 diabetes mellitus (T2DM). Euglycemic diabetic ketoacidosis (EDKA) and Fournier’s gangrene (FG) are uncommon advers effects of SGLT2 inhibitors. We report a case of a 52-year-old man who developed FG and EDKA after starting the SGLT2 inhibitor empagliflozin.Case Presentation: A-52 years old male patient attended to ...

Introduction: Sodium/glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycemic agents that are increasingly used in the management of type 2 diabetes mellitus (T2DM). They are now recommended as second-line pharmacotherapy (in conjunction with metformin) in patients with type 2 diabetes and established atherosclerotic heart disease, heart failure or chronic kidney disease due to their favourable effects on cardiovascular and renal outcomes. We report a case of a ...